Integrated Somatic Mutation Network Diffusion Model for Stratification of Breast Cancer into Different Metabolic Mutation Subtypes

Background: Mutations in metabolism-related genes in somatic cells potentially lead to disruption of metabolic pathways, which results in patients exhibiting different molecular and pathological features. background: Mutations in metabolism-related genes in somatic cells potentially lead to disruption of metabolic pathways, which results in patients exhibiting different molecular and pathological features. Objective: In this study, we focused on somatic mutation data to investigate the significance of metabolic mutation typing in guiding the prognosis and treatment of breast cancer patients. objective: In this study, we focused on somatic mutation data to investigate the significance of metabolic mutation typing in guiding the prognosis and treatment of breast cancer patients. Methods: The somatic mutation profile of breast cancer patients was analyzed and smoothed by utilizing a network diffusion model within the protein-protein interaction network to construct a comprehensive somatic mutation network diffusion profile. Subsequently, a deep clustering approach was employed to explore metabolic mutation typing in breast cancer based on integrated metabolic pathway information and the somatic mutation network diffusion profile. In addition, we employed deep neural networks and machine learning prediction models to assess the feasibility of predicting drug responses through somatic mutation network diffusion profiles. Results: Significant differences in prognosis and metabolic heterogeneity were observed among the different metabolic mutation subtypes, characterized by distinct alterations in metabolic pathways and genetic mutations, and these mutational features offered potential targets for subtype-specific therapies. Furthermore, there was a strong consistency between the results of the drug response prediction model constructed on the somatic mutation network diffusion profile and the actual observed drug responses. Conclusion: Metabolic mutation typing of cancer assists in guiding patient prognosis and treatment.